Menu

American Retired Seniors

Just another WordPress site

Eric Lefkofsky Is Changing Lives With the Help of Tempus

Does the name Eric Lefkofsky sound familiar? Have you heard this name previously? If you haven’t, the name Groupon should ring a bell. Eric is the creator of Groupon and as of right now, he remains a shareholder of the business but has decided to use his energy to focus more on his new business venture, Tempus.Tempus is a fairly new concept that allows for patients to have their DNA analyzed by professionals who can aim a better treatment plan towards their individual health needs. The Tempus business is partnered with a large collection of prominent hospitals that work with those in labs to help better understand the DNA of the cancer patients. The database will collect specific genomic DNA to compare to others and then begin a treatment plan specific to each individual case.

Technology is always changing and for this reason, someone needed to come up with a better understanding of the data needed for patients in order to help patients be treated better for their cancer. With Tempus, the technology is there to help those live longer lives than before. Now the physicians are able to collect all the information they need to make a better and more informed plan for their patients.There are a number of nonprofits as well as startups that work to help to find a cure or treatment of a disease.

The business industry is able to screen for more things as the cost has decreased to perform certain tests than ever before. It is also easier and cheaper to store the data needed to perform tests and get results.Because Eric worked hard to partner with prominent hospitals, the data that is collected is stored and analyzed. There is a 20,000 square foot lab that is used primarily for collecting and analyzing all data. This lab helps to build a DNA database as well as a patient profile which is used to help cancer patients.

 

Eric Lefkofsky, the Co-Founder of Tempus

As written in the article, “This Is What’s Missing in the Data-Centric Approach to Cancer”, by Barb Darrow, doctors need a lot of data, to make good decisions, for their patient’s treatment of cancer. Eric Lefkofsky co-founded the company Tempus, when his wife was diagnosed with cancer, and he realized the doctors weren’t using all of the data they had available to them. There were privacy issues blocking the collection of data from hospitals, doctors, and researchers, and he felt it was necessary to share the results of their treatments on the many people who came through their doors. With all the different medical issues and medications they each took, the results of their treatments were all different.

The new data will alert the doctors to multiple patient results, and they will be better equipped to determine which treatment is best for their patient. Tempus is designed to collect their patient’s records, take the personal information from the record, and give the treatment results back to the doctors, researchers, and hospitals, so that they can properly analyze what has been working and not working so well on their patients. Lefkofsky would like to see cancer patients treated on a more individual basis for their needs. He would also like to see companies, like CRISPR, who are looking into personalized vaccines to use the data for their own research.

Mr Lefkofsky earned his law degree from the University of Michigan Law. In 1994 he and his business partner, Bradley Keywell, took out a loan to buy Brandon Apparel, but it went under. In 1999, they started an internet business called, Starbelly, which they were able to sell for $240 million. Since then, Lefkofsky has co-founded Tempus, Lightbank, Groupon, Uptake Technologies, Mediaocean, InnerWorkings, and Global Logistics. He also started a foundation with his wife, Liz, called, the Lefkofsky Family Foundation. The foundation is private and focuses on improving the communities in the Chicago area, as well as, around the world. Eric Lefkofsky – Co-founder and CEO @ Tempus | Crunchbase

Clay Siegall’s Brilliant Role In Seeking Solutions To Cancer

Clay Siegall is the co-founder and chief executive officer of Seattle Genetics; a pharmaceutical company focused on developing biotechnology solutions for cancer. Under Siegall’s tenure, the group has developed innovative products including the much known antibody-drug conjugates aimed at helping patients. Clay Siegall was also influential in seeking the certification of the firm’s first antibody-drug conjugate, ADCETRIS by the Food and Drug Administration in 2011.

 

In a recent interview, Clay opened up on his role at Seattle Genetics and also shared his success story. Clay Siegall’s father was diagnosed with cancer when he was just nineteen years old. Unfortunately for him, he watched helplessly as his father’s condition deteriorated and he succumbed five years later, leaving Clay devastated. He was only twenty-four then, and when he earned a doctorate in genetics, he set on a path to help cancer patients. He did this by joining pharmaceutical research institutes the like of Bristol-Myers Squibb. It was here that he gained experience in running a company and had a chance to improve his leadership skills further. The work also brought him to Seattle and with the skills he had acquired, he founded Seattle Genetics with a commitment to treating cancer.

 

In his entrepreneur journey, Clay Siegall has learned the habit of seeking knowledge and interacting with deeply knowledgeable individuals as the key secret to success. Siegall is also apprehensive of the fact that progress in anything needs strong partnerships. This has been Seattle Genetics group’s primary business strategy as they have collaborated with other companies. This has led to the development of new ideas and approaches that have extended the firm’s reach, therefore, helping more patients.

 

About Clay Siegall

 

Clay Siegall is the co-founder of Seattle Genetics and also serves as the group’s President, CEO, and Chairman of the Board. Clay is a professional geneticist and holds an array of academic credentials including a doctorate in Genetics from George Washington University.

 

Apart from his role at Seattle Genetics, Clay Siegall also sits on boards of different corporations in diverse industries. Siegall is also the author of numerous publications and holds numerous patents.

Mikhail Blagosklonny/ Innovative Research Against Cancer

Mikhail Blagosklonny is a scientist that is involved in cancer research and aging. Mikhail Blagosklonny is currently a professor of oncology at the esteemed Roswell Park Cancer Institute, a position he was appointed to in 2009. Blagosklonny obtained his M.D in internal medicine from Pavlov State Medical University of St. Peterburg. He also received his PhD in experimental medicine and cardiology from the same university. During his career Blagosklonny has researched and investigated many different avenues regarding cancer and its devastating effects.

He has developed theories and approaches that can one day revolutionize cancer treatment. Mikhail Blagosklonny has a broad range of research interests, from molecular and cellular biology to clinical investigations. Some of his research is specifically inclusive of cell cycle, apoptosis, mitosis, signal transduction, oncogenes and tumor suppressors. Blagosklonny, because of his in-depth research has become a strong advocate for the use of Rapamycin a possible life extending drug in the fight against cancer and has a strong hypothesis regarding the role of TOR signaling in cancer and aging.

Rapamycin in regards to cancer seems to suppress tumors and is known to increase lifespan in mice. Targeted cancer therapies that do not target healthy cells are of special interest in his research. Before Mikhail Blagosklonny’s position at Roswell Park Cancer Institute, Blagosklonny previously held positions as Associate Professor of medicine at New York Medical College, Valhalla, NY and Senior Scientist at Ordway Research Institute, Albany, NY. Mikhail Blagosklonny has published 300 research articles including reviews and book chapters.

He is the editor of several publications including Cell cycle, and Aging both of which he was editor and chief. He was also a member of the editorial board for Cell Death and Differentiation and was associate editor of Cancer Biology and Therapy. Mikhail Blagosklonny is also the author of anti-cancer approaches also known as chemotherapeutic engineering and cell cyclotherapy. He continues to aid in the fight against cancer with his dedication to performing innovative and groundbreaking research. View his LinkedIn profile.